BioCentury
ARTICLE | Emerging Company Profile

Tolera: Delta Force Improves Tolerance

January 11, 2010 8:00 AM UTC

Corporate Profile

Tolera Therapeutics Inc. is developing a mAb against the alpha beta T cell receptor designed to improve upon the safety and tolerability of Genzyme Corp.'s Thymoglobulin, the market-leading antibody for induction therapy to prevent rejection of transplanted organs...